Financial payments made by pharmaceutical companies to the authors of Japanese hematology clinical practice guidelines between 2016 and 2017
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Health Policy
- Vol. 125 (3) , 320-326
Abstract
No abstract availableKeywords
Funding Information
- Ain Pharmacies and Waseda Chronicle
This publication has 16 references indexed in Scilit:
- Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databasesBMJ, 2019
- Pharmaceutical payments to certified oncology specialists in Japan in 2016: a retrospective observational cross-sectional analysisBMJ Open, 2019
- Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in JapanJAMA Network Open, 2019
- Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic TargetsCurrent Oncology Reports, 2019
- Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categoriesBMJ Open, 2019
- Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016JNCI: Journal of the National Cancer Institute, 2018
- Evaluating Industry Payments Among Dermatology Clinical Practice Guidelines AuthorsJAMA Dermatology, 2017
- Pharmaceutical Industry–Sponsored Meals and Physician Prescribing Patterns for Medicare BeneficiariesJAMA Internal Medicine, 2016
- Access to Costly New Hepatitis C Drugs: Medicine, Money, and AdvocacyClinical Infectious Diseases, 2015
- The future of immune checkpoint therapyScience, 2015